Novartis AG (NVS)
- Previous Close
97.34 - Open
97.75 - Bid 95.70 x 800
- Ask 97.95 x 800
- Day's Range
97.07 - 97.91 - 52 Week Range
92.19 - 108.78 - Volume
1,045,674 - Avg. Volume
1,610,965 - Market Cap (intraday)
198.471B - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
22.11 - EPS (TTM)
4.40 - Earnings Date Jul 18, 2024
- Forward Dividend & Yield 3.78 (3.88%)
- Ex-Dividend Date Mar 7, 2024
- 1y Target Est
114.51
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
www.novartis.com76,057
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NVS
Performance Overview: NVS
Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVS
Valuation Measures
Market Cap
197.27B
Enterprise Value
214.86B
Trailing P/E
22.11
Forward P/E
13.44
PEG Ratio (5yr expected)
4.64
Price/Sales (ttm)
4.23
Price/Book (mrq)
5.00
Enterprise Value/Revenue
4.50
Enterprise Value/EBITDA
11.72
Financial Highlights
Profitability and Income Statement
Profit Margin
31.94%
Return on Assets (ttm)
8.65%
Return on Equity (ttm)
19.83%
Revenue (ttm)
47.73B
Net Income Avi to Common (ttm)
9.11B
Diluted EPS (ttm)
4.40
Balance Sheet and Cash Flow
Total Cash (mrq)
9.7B
Total Debt/Equity (mrq)
68.63%
Levered Free Cash Flow (ttm)
13.39B
Research Analysis: NVS
Company Insights: NVS
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: NVS
Analyst Report: Novartis AG
Novartis is a pharmaceutical company based in Switzerland. Its portfolio is focused primarily on the areas of Immunology, Neuroscience, Oncology, Cardiovascular, Renal, and Metabolic therapies. The company employs more than 78,000 people and its medicines reach more than 280 million people worldwide.
RatingPrice TargetMarket Digest: NVS, AN, AVB, BA, DPZ, GOOGL, KMB, SNAP
With earnings season in full swing, the volume of insider transactions has fallen to seasonal lows, with only 615 transactions meeting the criteria for inclusion in Vickers Weekly Insider Report. While that is down from the recent weekly high of 2,284 transactions, there is still noteworthy data to consider.
Analyst Report: Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
RatingPrice TargetAnalyst Report: Novartis AG
Novartis is a pharmaceutical company based in Switzerland. Its portfolio is focused primarily on the areas of Immunology, Neuroscience, Oncology, Cardiovascular, Renal, and Metabolic therapies. The company employs more than 78,000 people and its medicines reach more than 280 million people worldwide.
RatingPrice Target